Search clinical trials for: Influenza vaccine

Total 6469 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States, Puerto Rico
Ology Bioservices

Completed

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Dalhousie University
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR); IWK Health Centre

Completed

Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Seasonal Influenza

Canada
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium
Imperial College London
Public Health England

Completed

Efficacy & Safety of Nasal Influenza Immunisation in Children (SNIFFLE-3)

Influenza Vaccines Efficacy and Safety

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Akron Children's Hospital

Completed

Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home

Influenza

United States
Region Örebro County
University of Cambridge; Örebro University, Sweden; The Swedish Heart and Lung...

Recruiting

Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE (ELIMINATE)

Cardiovascular Diseases | Inflammatory Response | Acute Myocardial Infarction

Sweden
University of North Carolina, Chapel Hill
U.S. National Science Foundation

Recruiting

Body and Social Behavior (BSB)

Inflammation | Psychology, Social | Defeat, Social | Interaction, Social

United States
Medicago

Completed

Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Influenza | Respiratory Tract Disease

Canada
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Influenza

Russian Federation
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

HIV Infections | H1N1 Influenza Virus

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry

Pregnancy | Influenza

United States
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
University of Witwatersrand, South Africa

Completed

Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (TIV_HIV_TB)

HIV | Tuberculosis | Influenza

South Africa
Hualan Biological Bacterin Co. Ltd.

Completed

Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population

Influenza A
GlaxoSmithKline

Completed

Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine

Haemophilus Influenzae Type b Disease

China
GlaxoSmithKline

Completed

Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
Novartis
Novartis Vaccines

Withdrawn

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older

Influenza

United Kingdom
Takeda

Completed

Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants

Influenza Infection
Abbott

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Influenza

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza

Italy
Novartis Vaccines

Completed

Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008

Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Emory University

Completed

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above

Influenza | Human

Germany
Crucell Holland BV

Completed

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

Influenza

Belgium
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza

United States
Centers for Disease Control and Prevention

Unknown

Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses

Influenza

United States
Isconova AB

Unknown

Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers

Influenza

Hungary
Abbott Biologicals
Quintiles, Inc.

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season

Influenza

Belgium, Germany
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Influenza

United States
ModernaTX, Inc.

Completed

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

Seasonal Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China

Influenza

China
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Hematologic Disorder

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Seqirus

Completed

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

Influenza

Turkey, Philippines, Thailand, Malaysia, Lithuania, Colombia, Czechia, Estonia, Bulgaria, Latvia, Poland, Romania
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand
Robert J. Pignolo
Genome Protection, Inc

Completed

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

Healthy

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Influenza

United States, Canada
Changchun BCHT Biotechnology Co.
National Institutes for Food and Drug Control, China; Simoon Record Pharma... and other collaborators

Completed

A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

Influenza

China
Novartis Vaccines

Completed

Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children

Haemophilus Influenzae Type B Infection

Korea, Republic of
Butantan Institute

Completed

Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly

Influenza

3

Subscribe